Phibro Animal Health (NASDAQ:PAHC) reported record fiscal 2026 sales and a sharp increase in adjusted EBITDA, supported by growth in its Animal Health and Mineral Nutrition businesses, the integration of its acquired Zoetis medicated feed additive portfolio, and operational initiatives under its Phi
Phibro Animal Health (NASDAQ:PAHC) held its fourth-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access
Animal health products manufacturer Phibro Animal Health (NASDAQ:PAHC) announced better-than-expected revenue in Q2 CY2026, with sales up 4.8% year on year t...
Animal health products manufacturer Phibro Animal Health (NASDAQ:PAHC) will be reporting earnings this Wednesday afternoon. Here’s what investors should know...
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in th...
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Phibro Animal Hea...
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as...
Value investing has produced some of the world’s most famous investing billionaires, including Warren Buffett, David Einhorn, and Seth Klarman, who built the...
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking a...
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr...
What Happened? Shares of animal health products manufacturer Phibro Animal Health (NASDAQ:PAHC) jumped 10.2% in the afternoon session after a director, E. Th...
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk tha...
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resou...
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remember...
Over the past six months, Phibro Animal Health’s shares (currently trading at $36.72) have posted a disappointing 18.5% loss, well below the S&P 500’s 11.5% ...
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord...
Phibro Animal Health (NASDAQ:PAHC) reported fiscal third-quarter 2026 results that management characterized as a “strong third quarter,” with growth in sales and adjusted earnings and updated full-year guidance that raised the lower end of several key ranges.
Third-quarter results show higher sales
Animal health products manufacturer Phibro Animal Health (NASDAQ:PAHC) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 10...
